<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00832611</url>
  </required_header>
  <id_info>
    <org_study_id>ROX IX</org_study_id>
    <nct_id>NCT00832611</nct_id>
  </id_info>
  <brief_title>Study of the Effect of the ROX AC1 on Exercise Capacity and Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <official_title>A Study of the Effect of the ROX Percutaneous Arteriovenous Fistula System (ROX AC1) on Exercise Capacity and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ROX Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ROX Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the efficacy of ROX AC1 (with respect to exercise capacity and quality of
      life) in patients with COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease that leads to irreversible
      changes in the lung structure, but also to systemic changes in the body that can influence
      the severity of the disease. The irreversible changes to the lungs can be seen in limitations
      in the pulmonary function. The purpose of this clinical investigation is to evaluate the
      performance and efficacy of the ROX AC1 on exercise capacity and respiratory quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in exercise capacity.</measure>
    <time_frame>12 weeks post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life.</measure>
    <time_frame>12 weeks post-procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Experimental: Group A Anastomotic Coupler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: ROX Anastomotic Coupler System (ACS). The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Arteriovenous Fistula (ROX AC1)</intervention_name>
    <description>The percutaneous creation of an arteriovenous fistula.</description>
    <arm_group_label>Experimental: Group A Anastomotic Coupler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of advanced Chronic Obstructive Pulmonary Disease (COPD) must be made on the
             basis of current findings, medical history and physical examination.

        Exclusion Criteria:

          -  Subject not qualifying because of physical or psychological condition that may put
             them at risk of participating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Vogelmeier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Gieβen und Marburg, Standort Marburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Gieβen und Marburg, Standort Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>D-35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Cooper CB, Celli B. Venous admixture in COPD: pathophysiology and therapeutic approaches. COPD. 2008 Dec;5(6):376-81. doi: 10.1080/15412550802522783.</citation>
    <PMID>19353352</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2009</study_first_submitted>
  <study_first_submitted_qc>January 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2009</study_first_posted>
  <last_update_submitted>January 27, 2015</last_update_submitted>
  <last_update_submitted_qc>January 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Disease</keyword>
  <keyword>Chronic Airflow Obstruction</keyword>
  <keyword>Chronic Bronchitis</keyword>
  <keyword>Chronic Emphysema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

